JP2023505218A5 - - Google Patents
Info
- Publication number
- JP2023505218A5 JP2023505218A5 JP2022533414A JP2022533414A JP2023505218A5 JP 2023505218 A5 JP2023505218 A5 JP 2023505218A5 JP 2022533414 A JP2022533414 A JP 2022533414A JP 2022533414 A JP2022533414 A JP 2022533414A JP 2023505218 A5 JP2023505218 A5 JP 2023505218A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093006A JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944589P | 2019-12-06 | 2019-12-06 | |
| US62/944,589 | 2019-12-06 | ||
| US202063055085P | 2020-07-22 | 2020-07-22 | |
| US63/055,085 | 2020-07-22 | ||
| US202063057769P | 2020-07-28 | 2020-07-28 | |
| US63/057,769 | 2020-07-28 | ||
| PCT/US2020/063395 WO2021113701A1 (en) | 2019-12-06 | 2020-12-04 | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093006A Division JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505218A JP2023505218A (ja) | 2023-02-08 |
| JP2023505218A5 true JP2023505218A5 (enExample) | 2023-12-08 |
| JP7693672B2 JP7693672B2 (ja) | 2025-06-17 |
Family
ID=74106148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533414A Active JP7693672B2 (ja) | 2019-12-06 | 2020-12-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| JP2025093006A Pending JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093006A Pending JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11919965B2 (enExample) |
| EP (1) | EP4069373A1 (enExample) |
| JP (2) | JP7693672B2 (enExample) |
| KR (1) | KR20220110510A (enExample) |
| CN (1) | CN114929343B (enExample) |
| AU (1) | AU2020398167A1 (enExample) |
| CA (1) | CA3160352A1 (enExample) |
| IL (1) | IL293288A (enExample) |
| MX (1) | MX2022006714A (enExample) |
| WO (1) | WO2021113701A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| EP4426437A4 (en) * | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN117886939B (zh) * | 2023-12-15 | 2024-07-26 | 康众(广东)生物医药有限公司 | 一组抗bcma的纳米抗体及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| TW202611075A (zh) * | 2024-05-13 | 2026-03-16 | 美商再生元醫藥公司 | 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法 |
| WO2026059923A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| WO2026059917A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| ES2954153T3 (es) * | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| UA126657C2 (uk) * | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| KR102520731B1 (ko) * | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) * | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| KR20210143246A (ko) * | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
-
2020
- 2020-12-04 JP JP2022533414A patent/JP7693672B2/ja active Active
- 2020-12-04 WO PCT/US2020/063395 patent/WO2021113701A1/en not_active Ceased
- 2020-12-04 CA CA3160352A patent/CA3160352A1/en active Pending
- 2020-12-04 KR KR1020227021340A patent/KR20220110510A/ko active Pending
- 2020-12-04 EP EP20834037.2A patent/EP4069373A1/en active Pending
- 2020-12-04 MX MX2022006714A patent/MX2022006714A/es unknown
- 2020-12-04 IL IL293288A patent/IL293288A/en unknown
- 2020-12-04 CN CN202080090951.6A patent/CN114929343B/zh active Active
- 2020-12-04 US US17/112,564 patent/US11919965B2/en active Active
- 2020-12-04 AU AU2020398167A patent/AU2020398167A1/en active Pending
-
2024
- 2024-02-01 US US18/429,887 patent/US20250051466A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093006A patent/JP2025131696A/ja active Pending